The Fight Against Measles
description
Transcript of The Fight Against Measles
![Page 1: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/1.jpg)
The Present Situation
The Strategies
The Vaccination
The Controversy
The Fight Against Measles
![Page 2: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/2.jpg)
• About 20 million cases each year around the globe. 2011 UK- 804 cases Ireland – 173 cases Europe - more than 26,000 cases
8 deaths 24 cases measles encephalitis• Africa and Asia , remains one of leading causes of
death in children. – WHO - 164,000 people died from measles in 2008, most younger than 5 years old.
Recent Outbreaks
![Page 3: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/3.jpg)
•Increase in measles cases and deaths in recent months•Prevalent in famine and drought areas•Unvaccinated children forced to live in cramped refugee camps•Somalia – 24%of 1yr olds immunized in country
Recent Outbreaks (2)
![Page 4: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/4.jpg)
Increase in US cases •over 92% population vaccinated•Dropped due to importation of disease from WHO European Regions and South East Asian regions.•33 countries in WHO European Region have increased measles cases
Eradication
![Page 5: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/5.jpg)
![Page 6: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/6.jpg)
MMR VaccineDeveloped in 1960s by Maurice Hilleman3 live attenuated virusesFirst dose ~1 year, second ~5 years.Before vaccination, measles “as inevitable as death and taxes”.Now contracted by <1% of individuals under 30 in countries with routine childhood vaccinationPrevents illness, disability, death.
![Page 7: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/7.jpg)
WHO Strategy 1994 - 2004Aim: Vaccinate >90% in all districtsAll children to get second dose71% of targeted children in 1999 -> 76% in 2004Sub-Saharan Africa – 49% -> 65%South Asia – 54% -> 61%2004 – 168 counties (88%) offered second round
![Page 8: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/8.jpg)
MMR in IrelandFirst dose at 12 monthsSecond dose (not booster) at 4-5 yearsThrough school/HSE or GPRecent outbreaks of measles and mumps due to missed second dose
![Page 9: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/9.jpg)
1985 - Monocomponent measles vaccine introduced- 10,000 cases in that year reduced to 201 in 19871988- combined MMR introduced -12-15months1992- Second dose recommended- 10-15 years1999- Age of second dose reduced to 4-5 yearsChildhood vaccination Schedule for children born after 1st July 2008- Free From the Department of Health, HSE• 12months from GP• 4-5 yrs from GP or in School • Primary School Immunisation Programme
Vaccination Strategy- Ireland
![Page 10: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/10.jpg)
Outbreak in 1993- affected 4,000 people2000- 1,600 cases resulted in 3 deathsFrom 2001 to 2006 – 1,562 cases • Rapid spread during these outbreaks due to:• Incomplete vaccination coverage• Susceptible pool of older unvaccinated children
Today- 221cases reported in 2011, so far (411 in 2010)• 85% occurred in North Dublin City
90% of children have received 1st dose by 24months
![Page 11: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/11.jpg)
Global mortality reduced by 78% , from estimated 733 000 deaths in 2000 to an estimated 164 000 deaths in 2008-78%The WHO region of America has sustained elimination since 2002The WHO has set a target of elimation of measles in remaining 4 out of 5 WHO regions by 2020.• This can only be achieved by
Increasing routine immunization coverage• improving surveillance systems• political and financial commitment
W.H.O-Measles Eradication
![Page 12: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/12.jpg)
• There are two treatments to protect against measles:
• MMR: measles, mumps and rubella vaccine.
• MMRV: measles, mumps, rubella, and varicella vaccine.
Vaccination
![Page 13: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/13.jpg)
• From nucleotide tests all vaccines were shown to be similar.
• At present the MMR vaccine has a 95% efficiency.
• First virus was obtained from David Edmonston in 1954.
• The virus strain was grown in chick embryos.
• Made the virus more suited to chicks than humans
• Similar attenuated vaccines around this time were developed.
Development
![Page 14: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/14.jpg)
• Control: reduce incidence of disease. Due to 95% efficiency a two dose strategy is need to prevent an accumulation of susceptible individuals.
• In 2010, about 85% of the world's children received one dose of measles vaccine by their first birthday through routine health services – up from 72% in 2000. Two doses of the vaccine are recommended to ensure immunity, as about 15% of vaccinated children fail to develop immunity from the first dose.
WHO: Eradiation PolicyControl
Outbreak Prevention
Eradication
![Page 15: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/15.jpg)
Children should be vaccinated with the MMR vaccine 12 to 15 months after birth and should receive a second dose at 4-5 year usually before the child enters school.
Before the vaccination programme was implemented in USA, between 3 to 4 million people were infected each year, with 400 to 500 dying
Measles is a highly contagious virus and was estimated there was 242,000 Measles deaths which equals 27 deaths every hour.
Measles Vaccine
![Page 16: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/16.jpg)
• The vaccine like many vaccines can cause allergic reactions, most people however do not have any problems with it.
• Mild problems: fever (1 in 6 doses), mild rash ( 1 in 20) or rare swelling of glands.
• Moderate problems: seizure (1 in 3,000 doses), temporary pain in joints ( 1 in 4 teenage and adult women) and temporary low platelet counts which can lead to a bleeding disorder ( 1 in 30,000 doses).
• Sever problems: 1 in 1 million: deafness, long-term seizures or comas and permanent brain damage.
MMR Vaccine Risks
![Page 17: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/17.jpg)
• Has a fever• Is taking steroids• Has had another live
attenuated vaccine in the last three days
• Is receiving chemotherapy/radiotherapy
• Has a compromised immune system
Less safe if recipient...
![Page 18: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/18.jpg)
Developing Countries Immunodeficiency
Individuals with low immune responses can’t handle certain vaccines due to the presence of attenuated or live virus.
• Presence of maternal antibodies during first 9 months of life reduces efficiency of immunization.
• Measles virus infects children by the respiratory tracts and little of the maternal antibodies will be transduced onto mucosal surfaces
Problems with Vaccine
![Page 19: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/19.jpg)
Aerosol delivery and high titre vaccinations to overcome problems in vaccinating young infants.
1. Recombinant virus2. Immune-
stimulating complexes
3. DNA vaccination
Advancements
![Page 20: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/20.jpg)
Controversy:Wakefield et al. 1998
![Page 21: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/21.jpg)
• 12 Children with Gastrointestinal symptoms, lost acquired skills including communication
• In 8 children, parents and/or physicians linked onset of behavioural problems with MMR
• Main cause of public concern
Wakefield et al. 1998
![Page 22: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/22.jpg)
• Wakefield: “I cannot support the continued use of these vaccines in combination…”
• Public uproar & slump in MMR vaccinations• Brian Deer Sunday Times investigation 2003-
2011• Prof. John O’ Leary slander
Media Coverage
![Page 23: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/23.jpg)
• Hornig et al. 2008 replications• Wakefield foul play
Evidence against autism link & aftermath of investigation
![Page 24: The Fight Against Measles](https://reader036.fdocuments.net/reader036/viewer/2022062410/568164da550346895dd72baa/html5/thumbnails/24.jpg)
Referenceshttp://www.immunisation.ie/en/Downloads/NIACGuidelines/PDFFile_15482_en.pdfhttp://www.irishhealth.com/article.html?id=780http://www.immunisation.ie/en/Downloads/PDFFile_15371_en.pdfhttp://www.who.int/immunization_monitoring/diseases/measlesreportedcasesbycountry.pdfhttp://www.immunisation.ie/en/ChildhoodImmunisation/PrimaryImmunisationSchedule/http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_18-en.pdfhttp://www.who.int/immunization/newsroom/news_wha_2010_measles_eradication/en/index.htmlwww.braindeer.comhttp://www.who.int/mediacentre/factsheets/fs286/en/http://www.cdc.gov/vaccines/vpd-vac/measles/default.htmhttp://www.immunisation.ie/en/ChildhoodImmunisation/VaccinePreventableDiseases/MMR/J. Wakefield, S. H. Murch, A. Anthony, J. Linnell, D. M. Casson, M. Malik, M. Berelowitz, A. P. Dhillon, M. A. Thomson (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. T. F. Wild (1999) Measles vaccines, new developments and immunization strategies. Vaccine 17; 1726-1729.